Literature DB >> 23457159

Scleroderma lung disease.

Joshua J Solomon1, Amy L Olson, Aryeh Fischer, Todd Bull, Kevin K Brown, Ganesh Raghu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23457159      PMCID： PMC4103193          DOI： 10.1183/09059180.00005512

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN： 0905-9180


× No keyword cloud information.
  176 in total

Review 1.  Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.

Authors:  Zeenat Safdar
Journal:  Respir Med       Date:  2011-01-26       Impact factor: 3.415

Review 2.  New insights into the pathogenesis of systemic sclerosis.

Authors:  Mathieu C Tamby; Youri Chanseaud; Loïc Guillevin; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2003-05       Impact factor: 9.754

3.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

Authors:  Vallerie V McLaughlin; Raymond L Benza; Lewis J Rubin; Richard N Channick; Robert Voswinckel; Victor F Tapson; Ivan M Robbins; Horst Olschewski; Melvyn Rubenfire; Werner Seeger
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

4.  Spontaneous pneumothorax in scleroderma.

Authors:  Jiun Yoon; David R Finger; Joseph S Pina
Journal:  J Clin Rheumatol       Date:  2004-08       Impact factor: 3.517

5.  Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Christina A Meadows; Michael G Risbano; Li Zhang; Mark W Geraci; Rubin M Tuder; David H Collier; Todd M Bull
Journal:  Chest       Date:  2010-09-09       Impact factor: 9.410

6.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

7.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

8.  Age and risk of pulmonary arterial hypertension in scleroderma.

Authors:  Lionel Schachna; Fredrick M Wigley; Betty Chang; Barbara White; Robert A Wise; Allan C Gelber
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

9.  Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

Authors:  Eric Hachulla; David Launay; Luc Mouthon; Olivier Sitbon; Alice Berezne; Loïc Guillevin; Pierre-Yves Hatron; Gérald Simonneau; Pierre Clerson; Marc Humbert
Journal:  Chest       Date:  2009-05-08       Impact factor: 9.410

10.  Reversible hypercapnic respiratory insufficiency in scleroderma caused by respiratory muscle weakness.

Authors:  A M Chausow; T Kane; D Levinson; J P Szidon
Journal:  Am Rev Respir Dis       Date:  1984-07
View more
  71 in total

Review 1.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

2.  Interstitial lung disease in South Africans with systemic sclerosis.

Authors:  Philippa Ashmore; Mohammed Tikly; Michelle Wong; Claudia Ickinger
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

3.  Characterisation of patients with interstitial pneumonia with autoimmune features.

Authors:  Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

4.  Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.

Authors:  Iago Pinal-Fernandez; Victor Pineda-Sanchez; Esther Pallisa-Nuñez; Carmen Pilar Simeon-Aznar; Albert Selva-O'Callaghan; Vicente Fonollosa-Pla; Miquel Vilardell-Tarres
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

Review 5.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

6.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

7.  Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.

Authors:  Aldo Carnevale; Mario Silva; Elisa Maietti; Gianluca Milanese; Marta Saracco; Simone Parisi; Elena Bravi; Fabio De Gennaro; Eugenio Arrigoni; Flavio Cesare Bodini; Enrico Fusaro; Carlo Alberto Scirè; Nicola Sverzellati; Alarico Ariani
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 2.980

8.  Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis.

Authors:  Mehmet Güli Çetinçakmak; Cemil Göya; Cihad Hamidi; Güven Tekbaş; Özlem Abakay; İbrahim Batmaz; Salih Hattapoğlu; Alpaslan Yavuz; Aslan Bilici
Journal:  Quant Imaging Med Surg       Date:  2016-02

9.  Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.

Authors:  D Sánchez-Cano; N Ortego-Centeno; J L Callejas; V Fonollosa Plá; R Ríos-Fernández; C Tolosa-Vilella; G Espinosa-Garriga; D Colunga-Argüelles; M V Egurbide-Arberas; M Rubio-Rivas; M Freire; J J Ríos-Blanco; L Trapiella-Martínez; M Rodríguez-Carballeira; A Marín-Ballvé; X Pla-Salas; C P Simeón-Aznar
Journal:  Rheumatol Int       Date:  2018-01-10       Impact factor: 2.631

Review 10.  [Current treatment of systemic scleroderma].

Authors:  Nicolas Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.